Expertise in
3
conditions

Pengpeng Xu

State Key Laboratory Of Medical Genomics, 
Shanghai, CN 
Expertise in
3
conditions
State Key Laboratory Of Medical Genomics, 
Shanghai, CN 
OverviewLocationsClinical Research

Overview

Pengpeng Xu practices in Shanghai, China. Xu is highly rated in 3 conditions, according to our data. Their top areas of expertise are Diffuse Large B-Cell Lymphoma (DLBCL), B-Cell Lymphoma, Non-Hodgkin Lymphoma, and T-Cell Lymphoma.

Their clinical research consists of co-authoring 41 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years.

Locations

State Key Laboratory Of Medical Genomics, Shanghai, 200025, China
Other Locations
Jiangsu Key Laboratory Of ASIC Design, Nantong, 226019, China
Suzhou, 215123, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 2, Open-Label Study to Evaluate the Safety and Efficacy of Chidamide Combined With CHOP(Cyclophosphamide, Doxorubicin, Vincristine, Prednisone ) in Untreated Subjects With Angioimmunoblastic T Cell Lymphoma
A Phase 2, Open-Label Study to Evaluate the Safety and Efficacy of Chidamide Combined With CHOP(Cyclophosphamide, Doxorubicin, Vincristine, Prednisone ) in Untreated Subjects With Angioimmunoblastic T Cell Lymphoma
Enrollment Status: Unknown
Publish Date: April 20, 2022
Intervention Type: Drug
Study Drugs: Chidamide, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone
Study Phase: Phase 2
A Phase 2, Open-Label Study to Evaluate the Safety and Efficacy of iR2 (Ibrutinib，Lenalidomide, Rituximab）in Untreated and Unfit Elderly Patients With Diffuse Large B-cell Lymphoma
A Phase 2, Open-Label Study to Evaluate the Safety and Efficacy of iR2 (Ibrutinib，Lenalidomide, Rituximab）in Untreated and Unfit Elderly Patients With Diffuse Large B-cell Lymphoma
Enrollment Status: Unknown
Publish Date: February 17, 2021
Intervention Type: Drug
Study Drugs: Ibrutinib, Lenalidomide, Rituximab
Study Phase: Phase 2
View 1 Less Clinical Trial

41 Total Publications

Clinical features and prognosis analysis of patients with follicular lymphoma: a real-world study in China.
Clinical features and prognosis analysis of patients with follicular lymphoma: a real-world study in China.
Journal: Annals of hematology
Published: March 12, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Xu's expertise for a condition
ConditionClose
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile